Skip to main content
Scilex Holding Co logo

Scilex Holding Co — Investor Relations & Filings

Ticker · SCLX ISIN · US80880W2052 LEI · 529900SPEA2C7YTTYP45 US Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-02-03 Regulatory Filings
Country US United States of America
Listing US SCLX

About Scilex Holding Co

https://www.scilexholding.com/

Scilex Holding Co. is a company focused on the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company's portfolio targets indications with high unmet medical needs and features therapies with proprietary drug delivery systems. These systems include an advanced topical patch technology for optimized drug delivery through the skin, an anti-inflammatory oral solution designed for individualized dosing in high-risk patients, and a liquid ready-to-use analgesic for migraine relief. Scilex aims to provide effective alternatives to opioid medications to improve patient quality of life.

Recent filings

Filing Released Lang Actions
424B3
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed pursuant to the Securities Exchange Act of 1934. It includes a prospectus supplement related to a resale of common stock shares, updates to a previously filed prospectus, and disclosures about a stock dividend by the controlling stockholder. The document contains detailed regulatory disclosures, exhibits including a FAQ supplement and a press release, and signatures. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or presentation. The primary nature is a regulatory filing providing material event disclosure and supplemental information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-02-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes references to Regulation FD Disclosure and exhibits such as a FAQ Supplement Disclosure and a press release. There is no detailed financial data or comprehensive report content, but rather an announcement of supplemental information posted on the company's website. The document length is 4689 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K.
2023-02-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes preliminary unaudited financial results for a one-month period ending January 31, 2023, but it explicitly states these are preliminary estimates and not audited or final financial statements. The document is short (4629 characters) and primarily serves as an announcement of preliminary financial results rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It also does not fit other categories like Earnings Release (ER) because it provides preliminary estimates rather than finalized quarterly results. Given these factors, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-02-02 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed pursuant to the Securities Exchange Act of 1934, dated January 30, 2023. It includes a prospectus supplement related to a resale of common stock shares and a Current Report on Form 8-K that discloses Regulation FD information about a stock dividend by the controlling stockholder, Sorrento Therapeutics, Inc. The document contains detailed information about the stock dividend, record dates, payment dates, and FAQs for shareholders. It is not an annual or quarterly financial report, audit report, earnings release, or management discussion. It is a regulatory filing providing material event disclosure and supplemental prospectus information. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a mere announcement but a substantive regulatory filing. Confidence is high due to the clear identification of the form type and content.
2023-01-30 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, as indicated by the header and references to SEC rules and filing numbers. It includes a prospectus supplement related to a securities offering, details about stock and warrant issuances, and a stock dividend FAQ disclosure. The content focuses on updates and disclosures about securities offerings and corporate actions rather than comprehensive financial statements or management discussion. It is not an annual or quarterly report, earnings release, or management report. The document is a regulatory filing providing material information to investors and the SEC, consistent with the nature of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-01-30 English
424B3
Regulatory Filings Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to a registration statement on Form S-1, including a Current Report on Form 8-K dated January 30, 2023. The content focuses on a stock dividend by a controlling stockholder, Sorrento Therapeutics, Inc., distributing shares of Scilex Holding Company common stock. It includes detailed FAQs about the dividend, record dates, payment dates, and procedures for stockholders. The document is not a full financial report, earnings release, or management discussion but rather a regulatory filing updating investors on a capital transaction and related disclosures. It is primarily a Current Report on Form 8-K with exhibits and supplemental information. Therefore, the best classification is Regulatory Filings (RNS), as it does not fit into other specific categories like Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA) because it is a Form 8-K filing with supplemental information rather than a direct capital raise or share issuance announcement.
2023-01-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.